

Svasti Haricharan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4536508/publications.pdf>

Version: 2024-02-01

18
papers

633
citations

840585

11
h-index

794469

19
g-index

21
all docs

21
docs citations

21
times ranked

1232
citing authors

#	ARTICLE	IF	CITATIONS
1	The DNA damage repair landscape in Black women with breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210754.	1.4	6
2	Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. <i>Brain</i> , 2022, 145, 3383-3390.	3.7	3
3	Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. <i>Nature Communications</i> , 2021, 12, 2940.	5.8	14
4	Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. <i>Cancer Cell International</i> , 2021, 21, 266.	1.8	26
5	HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	11
6	Abstract 2521: Race specific differences in DNA damage repair dysregulation in breast cancer and association with outcome. , 2021, , .		0
7	Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers. <i>Translational Cancer Research</i> , 2020, 9, 4060-4064.	0.4	24
8	IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii93-ii93.	0.6	1
9	Endocrine therapy resistance: new insights. <i>Breast</i> , 2019, 48, S26-S30.	0.9	60
10	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. <i>Clinical Cancer Research</i> , 2018, 24, 4887-4899.	3.2	74
11	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. <i>Cell Reports</i> , 2018, 24, 1434-1444.e7.	2.9	73
12	DNA damage repair defects as a new class of endocrine treatment resistance driver. <i>Oncotarget</i> , 2018, 9, 36252-36253.	0.8	37
13	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 1168-1183.	7.7	58
14	Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?. <i>Oncoscience</i> , 2017, 4, 77-78.	0.9	4
15	Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER + Breast Cancer. <i>Cancer Cell</i> , 2016, 29, 249-250.	7.7	6
16	TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3216-25.	3.3	68
17	Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 211-220.	1.1	90
18	Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. <i>ELife</i> , 2013, 2, e00996.	2.8	42